About Haemostatix
Haemostatix is a Healthcare company based in Nottingham (United Kingdom) founded in 2003, and was acquired by Ergomed in May 2016. Developing new class of peptide based coagulant. Haemostatix has raised $2.43 million across 6 funding rounds from investors including University of Leicester, Royal Society of Chemistry and Albion Capital. The company has 11,995 employees. Its focus areas include Life Sciences, Wound Care and Drugs. Its legal entity is HAEMOSTATIX LIMITED.
Company details
Haemostatix has developed a new class of peptide-based coagulant, or haemostat, for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical products to treat surgical bleeding. Haemostatixs pipeline includes PeproStat Liquid, a topical liquid haemostat that is applied to wounds to control bleeding during surgery; and HXP12 ReadyFlow, a flowable and transparent haemostatic gel that can be applied to irregular bleeding sites.
- Headquarters Nottingham, United Kingdom
- Employees 11,995
- Stage Acquired
- SectorsHealthcare
- Website haemostatix.com
- Acquired by Ergomed (May 2016)
- Legal Name Haemostatix Limited
- Date of Incorporation 14 Mar, 2003
- Jurisdiction GUILDFORD, ENGLAND
- Net Profit-$199.58 K (USD)69as on Dec 31, 2020
- Total Equity Funding$2.43M (USD)
in 6 rounds
- Latest Funding Round$31.47K (USD), Grant
Jun 2015
- InvestorsUniversity of Leicester
& 10 more
- Employee Count11,995
- Acquired byErgomed
(May 2016)
Funding Insights of Haemostatix
Haemostatix has successfully raised a total of $2.43M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $31.47 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.43M
- Total Rounds 6
- Last Round Grant — $31,473
- First Round $742,639
(Nov 2010)
- Investors Count 10
All 6 funding rounds of Haemostatix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $31,473 | Grant | – | – | |
| Nov 2012 | $1.28M | Series A | – | Catapult Ventures, Spark Ventures | – |
| Oct 2012 | $2.25M | Grant | – | – | |
| Jun 2011 | $405,535 | Series A | – | – | |
| Nov 2010 | $742,639 | Series A | – | Spark Ventures, Catapult Ventures | – |
| Nov 2010 | $661,742 | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Haemostatix
Haemostatix has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include University of Leicester, Royal Society of Chemistry and Albion Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment solutions are provided by Catapult Ventures for growth. | catapult-ventures.com | Leicester, United Kingdom | ||
Early-stage tech and life science investments are made in Europe. | sparkventuremanagement.com | London, United Kingdom | ||
Venture capital investments are managed by Albion Capital. | 1996 | albion.capital | London, United Kingdom | |
| lachesisfund.co.uk | ||||
Impact investments are made in mission-led technology ventures. | nestainvestments.org.uk | London, United Kingdom | ||
| mobiusvc.com | ||||
A community focused on science & technology | 1841 | rsc.org | London, United Kingdom | |
Multiple courses and degrees are offered across diversified academic streams. | 1921 | le.ac.uk | Leicester, United Kingdom | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
| esperanteventures.com |
Investor details for Haemostatix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Haemostatix
4 dated milestones of Haemostatix across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Haemostatix is founded.
- Funding First funding round of $743K.
- Funding Latest funding round, Grant, of $31K.
- Exit Acquired by Ergomed.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Haemostatix
Haemostatix was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Haemostatix is headquartered in Nottingham, United Kingdom.
Haemostatix is a funded company, having raised a total of $2.43M across 6 funding rounds to date. The company's 1st funding round was a Series A of $742.64K, raised on Nov 2010.
Haemostatix has 11,995 employees.
Haemostatix has developed a new class of peptide-based coagulant, or haemostat, for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical products to treat surgical bleeding. Haemostatixs pipeline includes PeproStat Liquid, a topical liquid haemostat that is applied to wounds to control bleeding during surgery; and HXP12 ReadyFlow, a flowable and transparent haemostatic gel that can be applied to irregular bleeding sites.
Haemostatix has 11 investors. Key investors include University of Leicester, Royal Society of Chemistry, Albion Capital, Ergomed, and Catapult Ventures.
Haemostatix operates through Haemostatix Limited.
Yes. Haemostatix was acquired by Ergomed in May 2016.